Cargando…

Therapeutic Potential of α-Synuclein Evolvability for Autosomal Recessive Parkinson's Disease

The majority of Parkinson's disease (PD) is sporadic in elderly and is characterized by α-synuclein (αS) aggregation and other alterations involving mitochondria, ubiquitin-proteasome, and autophagy. The remaining are familial PD associated with gene mutations of either autosomal dominant or re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Jianshe, Ho, Gilbert, Takamatsu, Yoshiki, Masliah, Eliezer, Hashimoto, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632460/ https://www.ncbi.nlm.nih.gov/pubmed/34858569 http://dx.doi.org/10.1155/2021/6318067

Ejemplares similares

Therapeutic Potential of αS Evolvability for Neuropathic Gaucher Disease
por: Wei, Jianshe, et al.
Publicado: (2021)

Motor and Nonmotor Symptoms of Parkinson's Disease: Antagonistic Pleiotropy Phenomena Derived from α-Synuclein Evolvability?
por: Takamatsu, Yoshiki, et al.
Publicado: (2018)

Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy
por: Wei, Jianshe, et al.
Publicado: (2023)

Evolvability of Amyloidogenic Proteins in Human Brain
por: Hashimoto, Makoto, et al.
Publicado: (2018)

Adiponectin Paradox in Alzheimer's Disease; Relevance to Amyloidogenic Evolvability?
por: Waragai, Masaaki, et al.
Publicado: (2020)

Possible Role of the Polyglutamine Elongation in Evolution of Amyloid-Related Evolvability
por: Hashimoto, Makoto, et al.
Publicado: (2018)

Transgenerational Interaction of Alzheimer’s Disease with Schizophrenia through Amyloid Evolvability
por: Takamatsu, Yoshiki, et al.
Publicado: (2019)

Possible Role of Amyloid Cross-Seeding in Evolvability and Neurodegenerative Disease
por: Hashimoto, Makoto, et al.
Publicado: (2019)

Connecting Alzheimer’s Disease With Diabetes Mellitus Through Amyloidogenic Evolvability
por: Ho, Gilbert, et al.
Publicado: (2020)

Understanding Creutzfeldt-Jackob disease from a viewpoint of amyloidogenic evolvability
por: Hashimoto, Makoto, et al.
Publicado: (2020)

Evolvability and Neurodegenerative Disease: Antagonistic Pleiotropy Phenomena Derived from Amyloid Aggregates
por: Hashimoto, Makoto, et al.
Publicado: (2018)

α-Synuclein and DJ-1 as Potential Biological Fluid Biomarkers for Parkinson’s Disease
por: Waragai, Masaaki, et al.
Publicado: (2010)

Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2
por: Ho, Gilbert, et al.
Publicado: (2021)

Role of α- and β-Synucleins in the Axonal Pathology of Parkinson’s Disease and Related Synucleinopathies
por: Sekigawa, Akio, et al.
Publicado: (2015)

Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H ß-synuclein
por: Sekigawa, Akio, et al.
Publicado: (2012)

Adiponectin paradox as a therapeutic target of the cancer evolvability in aging
por: Takamatsu, Yoshiki, et al.
Publicado: (2020)

Adiponectin Paradox as a Therapeutic Target in Alzheimer’s Disease
por: Waragai, Masaaki, et al.
Publicado: (2020)

Possible Role of Amyloidogenic Evolvability in Dementia with Lewy Bodies: Insights from Transgenic Mice Expressing P123H β-Synuclein
por: Fujita, Masayo, et al.
Publicado: (2020)

Possible Alterations in β-Synuclein, the Non-Amyloidogenic Homologue of α-Synuclein, during Progression of Sporadic α-Synucleinopathies
por: Fujita, Masayo, et al.
Publicado: (2012)

Role of Synucleins in Alzheimer’s Disease
por: Crews, Leslie, et al.
Publicado: (2009)

A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain
por: Fujita, Masayo, et al.
Publicado: (2010)

Reconsideration of Alzheimer’s Disease Therapy from a Viewpoint of Amyloidogenic Evolvability
por: Ho, Gilbert, et al.
Publicado: (2022)

Animal Models of Autosomal Recessive Parkinsonism
por: Bastioli, Guendalina, et al.
Publicado: (2021)

Importance of adiponectin activity in the pathogenesis of Alzheimer's disease
por: Waragai, Masaaki, et al.
Publicado: (2017)

Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases
por: Takamatsu, Yoshiki, et al.
Publicado: (2017)

TOM40 Mediates Mitochondrial Dysfunction Induced by α-Synuclein Accumulation in Parkinson’s Disease
por: Bender, Andreas, et al.
Publicado: (2013)

Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson’s disease
por: Kim, Changyoun, et al.
Publicado: (2015)

Therapeutic Potential for CFTR Correctors in Autosomal Recessive Polycystic Kidney Disease
por: Yanda, Murali K., et al.
Publicado: (2021)

Mechanisms of mitochondrial quality control in autosomal recessive Parkinson’s disease
por: Corti, Olga
Publicado: (2015)

Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson’s Disease
por: Rockenstein, Edward, et al.
Publicado: (2016)

Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2
por: Kim, Changyoun, et al.
Publicado: (2016)

Intracellular A53T Mutant α-Synuclein Impairs Adult Hippocampal Newborn Neuron Integration
por: Regensburger, Martin, et al.
Publicado: (2020)

Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease
por: Kaul, Tiffany, et al.
Publicado: (2011)

Specific Detection of Physiological S129 Phosphorylated α-Synuclein in Tissue Using Proximity Ligation Assay
por: Arlinghaus, Ryan, et al.
Publicado: (2023)

Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
por: Ngolab, Jennifer, et al.
Publicado: (2017)

Correction to: Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
por: Ngolab, Jennifer, et al.
Publicado: (2020)

Potential for Therapeutic-Loaded Exosomes to Ameliorate the Pathogenic Effects of α-Synuclein in Parkinson’s Disease
por: Rademacher, David J.
Publicado: (2023)

Disease modifying effect of adiponectin in model of α-synucleinopathies
por: Sekiyama, Kazunari, et al.
Publicado: (2014)

Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson’s Disease/Dementia with Lewy Bodies
por: Price, Diana L., et al.
Publicado: (2016)

Early manifestation of depressive‐like behavior in transgenic mice that express dementia with Lewy body‐linked mutant β‐synuclein
por: Fujita, Masayo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fqf8kmj6h2c0mite55av85kv4c